AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04048057 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Modarete Intensity Continous Training: Medium intensity continuous exercise training will be performed. Exercise intensity will be adjusted as 50-70% of maximal power.~High Intensity Interval Training I: It will be four cycles consisting of 4 minute high intensity exercise phase and 3 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.~High Intensity Interval Training II: It will be 10 cycles consisting of 1 minute high intensity exercise phase and 1 minute active recovery phase. High intensity phase will be adjusted as 85-100% of maximal power and active recovery phase as 50-70% of maximal power.
Study NCT02077972 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High intensity whole-body infrared heating
Description: The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
Study NCT00682760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Korean Botulinum toxin type A (KbtxA) and Botox injection
Description: Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
Study NCT03716089 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic resection
Description: Laparoscopic surgery under general anesthesia
Study NCT03555955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 is administered as an intravenous (IV) infusion over approximately 90 minutes.
Study NCT04728074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The Entering Employment and Sustaining Work Program
Description: A structured, motivation and self-awareness based group intervention
Study NCT00682760 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Korean Botulinum toxin type A (KbtxA) and Botox injection
Description: Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
Study NCT03639688 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Threading on the left lip commissure
Description: Threading of the endotracheal tube over the fiberoptic bronchscope from the left lip commissure
Study NCT04728074 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: vocational rehabilitation
Description: An individual based, focused on desired job or occupation, face-to-face intervention
Study NCT04728074 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: vocational rehabilitation
Description: An individual based, focused on desired job or occupation, face-to-face intervention
Study NCT03296241 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: laser
Study NCT03296241 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham control
Study NCT03639688 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Threading on the right lip commmissure
Description: Threading of the endotracheal tube over the fiberoptic bronchoscope from the right lip commissure
Study NCT03887975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Monoplane Occlusion
Description: Monoplane and lingualized occlusion effect on force distribution
Study NCT03887975 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lingualized occlusion
Description: Monoplane and lingualized occlusion effect on force distribution
Study NCT01341236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: different nutrional regimen
Description: compare bolus versus intermittent nutrition
Study NCT01341236 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: comparison of different feeding regimens
Description: compare intermittent versus bolus nutrition
Study NCT03817931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticholinergic
Description: Tablet taken once daily.
Study NCT03817931 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Beta-3 Agonists, Adrenergic
Description: Tablet taken once daily.
Study NCT03817931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Functional magnetic resonance imaging (fMRI)
Description: All subjects have fMRI at baseline and again after 30 days
Study NCT03817931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Functional magnetic resonance imaging (fMRI)
Description: All subjects have fMRI at baseline and again after 30 days
Study NCT03817931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Rey Auditory Verbal Learning Test (RAVLT)
Description: All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
Study NCT03817931 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Rey Auditory Verbal Learning Test (RAVLT)
Description: All subjects have RAVLT at baseline and again after 30 days. RAVLT evaluates: short-term auditory-verbal memory, rate of learning, learning strategies, retroactive, and proactive interference, presence of confabulation of confusion in memory processes, retention of information, and differences between learning and retrieval.
Study NCT03739060 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous electric nerve stimulation
Description: Conventional transcutaneous electric nerve stimulation
Study NCT03739060 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous electric nerve stimulation
Description: Conventional transcutaneous electric nerve stimulation
Study NCT04255368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Water-soluble choline
Description: 600 mg choline as choline bitartrate
Study NCT04255368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fat-soluble choline
Description: 600 mg choline as phosphatidylcholine
Study NCT04255368 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No choline control
Description: No choline
Study NCT03211104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curcumin
Study NCT03211104 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01855490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Study NCT02355925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intrauterine injection of uhCG
Description: 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
Study NCT02355925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
Study NCT03032211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alfapump
Description: Implant Alfapump® System
Study NCT02013557 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-message reminder
Study NCT00211354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anecortave Acetate
Description: ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
Study NCT02355925 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control
Description: the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
Study NCT01675856 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Urgent endoscopy
Description: Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
Study NCT01675856 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Early endoscopy
Description: Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
Study NCT02148952 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WHO Safe Childbirth Checklist Program
Description: The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
Study NCT00348738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of >14g/dl, \<15g/dl is reached or until the end of the radiation therapy.
Study NCT03357796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03005
Description: 80 mg, oral tablets, single dose
Study NCT03357796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pristiq
Description: 50 mg, oral tablets, single dose
Study NCT03286543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPRINT Beta System
Description: The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator).
Study NCT03829462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: regorafenib tab 40 mg i.e 160 mg/day
Study NCT03829462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regorafenib
Description: regorafenib tab 40 mg i.e 160 mg/day
Study NCT03829462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: irinotecan 120 mg/m2 cycle 1, 150 mg/m2 cycle 2, 180 mg/m2 cycle 3 and more
Study NCT04522882 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: Actimetry will be performed at home to measure physical activity, sleep duration and patient chronotype for 7 days.
Study NCT04522882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Patients will complete food and medication intake questionnaires for 7 days.
Study NCT04522882 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose level and insulin administration
Description: Continuous subcutaneous glucose level (measured by continuous glucose monitor (CGM)) and the insulin doses delivered by the insulin pump will be collected for 7 days .
Study NCT03919084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: THRIVE screening and referral
Description: The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
Study NCT03919084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: THRIVE screening and referral
Description: The THRIVE screening tool includes questions to identify eight potentially unmet health-related social needs associated with health outcomes and healthcare utilization: housing and food insecurity, inability to afford medications, need for transportation, trouble paying for heat and electricity, need for employment or education, and difficulty taking care of children or other family members. The survey is written at a 3rd grade reading level, is available in multiple languages, and requires less than five minutes to complete. The paper screener consists of two parts: part one screens patients for health-related social needs in the eight domains. Part two asks patients to indicate the resources they want help accessing across the eight domains. Patients who request resources in one or more domains receive paper guides that describe available hospital and community resources to address the specific domain(s) indicated.
Study NCT03919084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacy Care Program services
Description: Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
Study NCT03919084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacy Care Program services
Description: Pharmacy services provided by a pharmacy liaison include assessing gaps in obtaining refills, identifying barriers to medication adherence, reviewing the patient's engagement in medical care, and developing an action plan with the patient. Action plans focus on strategies to increase medication adherence and engagement in care. The pharmacy liaison will also link the patient to a clinical pharmacist, when appropriate, and will assist the patient with prescription management. After the initial intake is completed, the pharmacy liaison will call patients monthly (or meet with them prior to or following scheduled appointments) over a twelve-month period to confirm medication adherence and address any new barriers to medication adherence and engagement in medical care. The pharmacy liaison in the control arm does not systematically initiate screening for health-related social needs.
Study NCT03919084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Navigation Services
Description: In traditional patient navigation programs, a lay person from the community guides individuals through the healthcare system to receive appropriate services. For the present study, the research team will train pharmacy liaisons (pharmacy technicians or pharmacy interns with at least a high school degree and four years of pharmacy experience) to provide patient navigation services, in addition to providing medication adherence support and assistance resolving barriers to accessing medication. In an effort to avoid duplication of services the patient navigation intervention will be delivered via a pharmacy liaison trained in patient navigation, thereby decreasing multiple intervention providers and increasing the potential for sustainability should the intervention prove effective.
Study NCT03919084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Motivational interviewing is a counseling method that encourages patient-centered discussions. Motivational interviewing will be delivered by the intervention arm pharmacy liaison-patient navigators to identify the patient's unmet needs and encourage the patient to adopt behavior change that will promote engagement with resources and services to mitigate or alleviate HRSN.
Study NCT03919084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linkage to Community Partner Organization
Description: The pharmacy liaison-patient navigator will partner with a community organization, Action for Boston Community Development (ABCD). ABCD will help connect patients receiving THRIVE+ to community resources including childcare, food, heating, and housing. The pharmacy liaison-patient navigator will interface directly with ABCD to coordinate receipt of resources for their patients.
Study NCT03592173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Paired TMS & Peripheral Nerve Stimulation
Description: Method of assessing neurophysiology and activity of the spinal cord
Study NCT03592173 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Paired TMS & Peripheral Nerve Stimulation
Description: Method of assessing neurophysiology and activity of the spinal cord
Study NCT04009824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AGS-v PLUS Vaccine
Description: Administered by subcutaneous injection
Study NCT01503970 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arthroscopic matrix encapsulated chondrocyte implantation
Description: Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
Study NCT04009824 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Montanide ISA-51 Adjuvant
Description: Administered by subcutaneous injection
Study NCT03928574 — intervention group
Intervention type: PROCEDURE
Intervention: Ultrasound-Guided Plane Block
Description: Ultrasound-Guided Plane Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
Study NCT03928574 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional Block
Description: Conventional Block Medial Brachial Cutaneous and the Intercostobrachial Nerves
Study NCT01369797 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: specific intervention
Description: Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed.
Study NCT03063372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomella pomegranate extract
Description: Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.
Study NCT03063372 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take a gelatin placebo twice daily for 28 days.
Study NCT01125384 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional swabbing
Description: physician swabs patient's throat according to standard rules before referral of the patient to throat swabbing by nurse.
Study NCT02030392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: Cognitive-behavioral intervention
Study NCT02030392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active control group
Description: Education and information
Study NCT01937559 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TXA)
Description: 1.5g of TXA in 100ml normal saline solution
Study NCT01937559 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid (TXA)
Description: 1.5g of TXA in 100ml normal saline solution
Study NCT01937559 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Study NCT01828281 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Description: All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.